FINAL RESULTS for the twelve months ended 31 December 2024

19th May 2025 - 7:30 am

ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is pleased to announce its Final Results for the twelve months ended 31 December 2024 (the “Period”).

Key Highlights (including post Period review)

Financials

  • Loss for the Period of £2.5m (2023: £2.9m)
  • Research and development expenses of £1.2m (2023: £2.0m)
  • Administrative expenses of £1.0m (2023: £1.0m)
  • Share based expense of £0.09m (2023: £0.14m)
  • Cash balance of £0.2m at 31 December 2024 (31 December 2023: £0.2m)
  • Lanstead derivative financial asset of £0.2m (2023: £0.6m)
  • Basic and diluted loss per share of 0.60p (2023: 0.81p)
  • Incanthera financial asset: shares of £nil (2023: £0.6m) – warrants of £nil (2023: £1)
  • On 13 February 2025 a £2.91 million fundraise completed, comprising:
    – Oversubscribed equity fundraise of £1.034m; plus
    – £1.85m subscription through Lanstead Capital

Portfolio
P140 technology platform

  • In January 2025, innovative groundbreaking advancements announced in our preclinical research program focused on P140 and the pathogenesis of autoimmune diseases. These findings pave the way for earlier and more accurate diagnostics; identifying patients most likely to respond to P140 therapy; and improved monitoring of the patient’s response to treatment with P140
  • In March 2025 a significant milestone announced in evidencing for the first time key hypotheses in the unique mechanism of action (“MOA”) of our P140 autoimmune technology platform. Importantly, these new discoveries highlight that: P140 has a unique MOA, P140 is non‐immunosuppressive, and P140 is effective and safe
  • These findings allow ImmuPharma to further expand its intellectual property portfolio, with additional new patents, strengthening the commercial viability of the P140 technology platform

Partnering opportunities

  • Based on recent progress and insights into the P140’s MOA and autoimmune disease, active discussions continue with a number of global commercial partners

Preclinical Portfolio

  • The core anti-infective program with antifungal (BioAMB) and antibacterial (BioCIN) candidates are progressing through pre-clinical studies

Incanthera

  • As confirmed on 1 April 2025, the warrants of 7,272,740 held in Incanthera, have been further extended to 30 September 2025, alongside a profit share agreement, if the warrant shares are exercised

Commenting on the statement and outlook Tim McCarthy, CEO and Chairman, said: “We have made significant scientific progress over 2024 and into 2025, most importantly, announcing innovative groundbreaking advancements in our preclinical research program focused on P140 and the pathogenesis of autoimmune diseases. Importantly, paving the way for earlier and more accurate diagnostics; identifying patients most likely to respond to P140 therapy; and improved monitoring of the patient’s response to treatment with P140.

In addition, we also announced a significant milestone in evidencing for the first time, key hypotheses in the unique mechanism of action (“MOA”) of our P140 autoimmune technology platform. Importantly, these new discoveries highlight that: P140 has a unique MOA, P140 is non‐immunosuppressive, and P140 is effective and safe.

As a Board, we remain focused on bringing our two key late-stage clinical assets, P140 for SLE and CIDP, closer to the market, and securing additional partnering deals for P140 as well as our earlier stage assets, specifically within our anti-infectives program.

In closing, we would like to thank our shareholders for their support as well as our staff, corporate and scientific advisers and our partners including CNRS and Avion.”

Full announcement  click here

ImmuPharma plc REPORT AND CONSOLIDATED FINANCIAL STATEMENT download here

 

Market Abuse Regulation (MAR) Disclosure

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF UK LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED. ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.

Share this article